Q-omics provides the consensus-scored MYO18A profile across patient tissues and cancer cell-line models. MYO18A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYO18A is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, MYO18A protein abundance shows 21,983 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where MYO18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO18A survival associations across molecular data types. MYO18A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO18A RNA expression–survival associations across cancer types. High MYO18A expression shows unfavorable associations in OV and BRCA, but favorable associations in KIRC, SCLC, UCS and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYO18A RNA expression.
This table summarizes MYO18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYO18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO18A shows lower tumor expression in THCA, UCEC, HNSC, KICH, COAD and BRCA. The THCA box plot shows higher MYO18A RNA expression in normal versus tumor tissue (log2 FC = −0.501, t-test p < 0.001).
This table shows molecular features associated with MYO18A in patient tissues and cancer cell lines. In patient samples, MYO18A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
